- Home
- DSS vs CMND Comparison
DSS vs CMND Comparison
Compare DSS & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSS
- CMND
- Stock Information
- Founded
- DSS 1984
- CMND 2017
- Country
- DSS United States
- CMND Canada
- Employees
- DSS N/A
- CMND N/A
- Industry
- DSS Containers/Packaging
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- DSS Consumer Discretionary
- CMND Health Care
- Exchange
- DSS Nasdaq
- CMND Nasdaq
- Market Cap
- DSS 7.3M
- CMND 6.5M
- IPO Year
- DSS N/A
- CMND N/A
- Fundamental
- Price
- DSS $0.92
- CMND $1.38
- Analyst Decision
- DSS
- CMND
- Analyst Count
- DSS 0
- CMND 0
- Target Price
- DSS N/A
- CMND N/A
- AVG Volume (30 Days)
- DSS 19.0K
- CMND 96.0K
- Earning Date
- DSS 03-26-2025
- CMND 01-22-2025
- Dividend Yield
- DSS N/A
- CMND N/A
- EPS Growth
- DSS N/A
- CMND N/A
- EPS
- DSS N/A
- CMND N/A
- Revenue
- DSS $25,019,000.00
- CMND N/A
- Revenue This Year
- DSS N/A
- CMND N/A
- Revenue Next Year
- DSS N/A
- CMND N/A
- P/E Ratio
- DSS N/A
- CMND N/A
- Revenue Growth
- DSS N/A
- CMND N/A
- 52 Week Low
- DSS $0.77
- CMND $0.95
- 52 Week High
- DSS $2.30
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- DSS 53.63
- CMND 49.60
- Support Level
- DSS $0.81
- CMND $1.35
- Resistance Level
- DSS $0.97
- CMND $1.43
- Average True Range (ATR)
- DSS 0.06
- CMND 0.08
- MACD
- DSS 0.01
- CMND -0.00
- Stochastic Oscillator
- DSS 68.18
- CMND 43.75
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.